CN Patent

CN102083312B — 苯磺酰胺噻唑和噁唑化合物

Assigned to Novartis AG · Expires 2014-08-27 · 12y expired

What this patent protects

本发明提供噻唑磺酰胺和噁唑磺酰胺化合物，包含该化合物的组合物，及其制备方法和它们用作药剂的方法。

USPTO Abstract

本发明提供噻唑磺酰胺和噁唑磺酰胺化合物，包含该化合物的组合物，及其制备方法和它们用作药剂的方法。

Drugs covered by this patent

dabrafenib-mesylate (DABRAFENIB MESYLATE)

Patent Metadata

Patent number: CN102083312B
Jurisdiction: CN
Classification: —
Expires: 2014-08-27
Drug substance claim: No
Drug product claim: No
Assignee: Novartis AG
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.